Academy of Finland has granted a Key Project funding for Dr. Timo Myöhänen’s project titled “Prolyl oligopeptidase ligands – a possibility for a common drug therapy for several neurodegenerative diseases?”. Key Funding is a novel type of grant from Academy of Finland, and it is aiming more to look for possibilities to commercialize the research. The grant period is 2 years, and the value 300,000 euros. View the decisions here.